Literature DB >> 24142271

Inhibitory effect of doxycycline against dengue virus replication in vitro.

Hussin A Rothan1, Zulqarnain Mohamed, Mohammadjavad Paydar, Noorsaadah Abd Rahman, Rohana Yusof.   

Abstract

Doxycycline is an antibiotic derived from tetracycline that possesses antimicrobial and anti-inflammatory activities. Antiviral activity of doxycycline against dengue virus has been reported previously; however, its anti-dengue properties need further investigation. This study was conducted to determine the potential activity of doxycycline against dengue virus replication in vitro. Doxycycline inhibited the dengue virus serine protease (DENV2 NS2B-NS3pro) with an IC50 value of 52.3 ± 6.2 μM at 37 °C (normal human temperature) and 26.7 ± 5.3 μM at 40 °C (high fever temperature). The antiviral activity of doxycycline was first tested at different concentrations against DENV2 using a plaque-formation assay. The virus titter decreased significantly after applying doxycycline at levels lower than its 50 % cytotoxic concentration (CC50, 100 μM), showing concentration-dependent inhibition with a 50 % effective concentration (EC50) of approximately 50 μM. Doxycycline significantly inhibited viral entry and post-infection replication of the four dengue serotypes, with serotype-specific inhibition (high activity against DENV2 and DENV4 compared to DENV1 and DENV3). Collectively, these findings underline the need for further experimental and clinical studies on doxycycline, utilizing its anti-dengue and anti-inflammatory activities to attenuate the clinical symptoms of dengue virus infection.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24142271     DOI: 10.1007/s00705-013-1880-7

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  29 in total

1.  The NF-κB inhibitor, SC75741, is a novel antiviral against emerging tick-borne bandaviruses.

Authors:  Crystal A Mendoza; Satoko Yamaoka; Yoshimi Tsuda; Keita Matsuno; Carla M Weisend; Hideki Ebihara
Journal:  Antiviral Res       Date:  2020-12-06       Impact factor: 5.970

Review 2.  Repurposing of antibiotics for clinical management of COVID-19: a narrative review.

Authors:  Abdourahamane Yacouba; Ahmed Olowo-Okere; Ismaeel Yunusa
Journal:  Ann Clin Microbiol Antimicrob       Date:  2021-05-21       Impact factor: 3.944

3.  Ivermectin in combination with doxycycline for treating COVID-19 symptoms: a randomized trial.

Authors:  Reaz Mahmud; Md Mujibur Rahman; Iftikher Alam; Kazi Gias Uddin Ahmed; A K M Humayon Kabir; S K Jakaria Been Sayeed; Mohammad Aftab Rassel; Farhana Binte Monayem; Md Shahidul Islam; Mohammad Monirul Islam; Anindita Das Barshan; Mohammad Mahfuzul Hoque; Md Uzzal Mallik; Mohammad Abdullah Yusuf; Mohammad Zaid Hossain
Journal:  J Int Med Res       Date:  2021-05       Impact factor: 1.671

4.  A combination of doxycycline and ribavirin alleviated chikungunya infection.

Authors:  Hussin A Rothan; Hirbod Bahrani; Zulqarnain Mohamed; Teow Chong Teoh; Esaki M Shankar; Noorsaadah A Rahman; Rohana Yusof
Journal:  PLoS One       Date:  2015-05-13       Impact factor: 3.240

5.  Doxycycline as a potential partner of COVID-19 therapies.

Authors:  Alexandre E Malek; Bruno P Granwehr; Dimitrios P Kontoyiannis
Journal:  IDCases       Date:  2020-06-06

6.  Drug repositioning for dengue haemorrhagic fever by integrating multiple omics analyses.

Authors:  Takayuki Amemiya; M Michael Gromiha; Katsuhisa Horimoto; Kazuhiko Fukui
Journal:  Sci Rep       Date:  2019-01-24       Impact factor: 4.379

7.  An in vitro study of dual drug combinations of anti-viral agents, antibiotics, and/or hydroxychloroquine against the SARS-CoV-2 virus isolated from hospitalized patients in Surabaya, Indonesia.

Authors:  Andang Miatmoko; Eryk Hendrianto; Deya Karsari; Aristika Dinaryanti; Nora Ertanti; Igo Syaiful Ihsan; Disca Sandyakala Purnama; Tri Pudy Asmarawati; Erika Marfiani; Alfian Nur Rosyid; Prastuti Asta Wulaningrum; Herley Windo Setiawan; Imam Siswanto; Ni Nyoman Tri Puspaningsih
Journal:  PLoS One       Date:  2021-06-18       Impact factor: 3.240

Review 8.  Potential Anti-COVID-19 Therapeutics that Block the Early Stage of the Viral Life Cycle: Structures, Mechanisms, and Clinical Trials.

Authors:  Rami A Al-Horani; Srabani Kar; Kholoud F Aliter
Journal:  Int J Mol Sci       Date:  2020-07-23       Impact factor: 5.923

9.  A novel plan to deal with SARS-CoV-2 and COVID-19 disease.

Authors:  Raphael B Stricker; Melissa C Fesler
Journal:  J Med Virol       Date:  2020-06-02       Impact factor: 20.693

10.  Computational insights into tetracyclines as inhibitors against SARS-CoV-2 Mpro via combinatorial molecular simulation calculations.

Authors:  Shiv Bharadwaj; Kyung Eun Lee; Vivek Dhar Dwivedi; Sang Gu Kang
Journal:  Life Sci       Date:  2020-07-09       Impact factor: 6.780

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.